Cell biology

Humanigen to Present at Roth Conference

Friday, March 5, 2021 - 9:32pm

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Key Points: 
  • Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
  • In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
  • For more information, visit www.humanigen.com and follow Humanigen on LinkedIn , Twitter and Facebook .

Vor Biopharma to Present at the Barclays Global Healthcare Conference

Friday, March 5, 2021 - 8:00pm

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barclays Global Healthcare Conference, which will take place virtually on March 9-11, 2021.

Key Points: 
  • CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barclays Global Healthcare Conference, which will take place virtually on March 9-11, 2021.
  • Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 11, 2021, at 3:00 p.m. E.T.
  • An archived replay of the webcast will be available on the Company's website following the conference.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.

Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer

Thursday, March 4, 2021 - 12:00pm

Talaris Therapeutics, Inc., a late- clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune or metabolic disorders, today announced the appointment of Mary Kay Fenton as Chief Financial Officer.

Key Points: 
  • Talaris Therapeutics, Inc., a late- clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune or metabolic disorders, today announced the appointment of Mary Kay Fenton as Chief Financial Officer.
  • Her appointment rounds out Talaris experienced leadership team and sets us up well for continued success, said Scott Requadt, Chief Executive Officer of Talaris.
  • Before that role, she was the Chief Financial Officer and Chief Operating Officer of Semma Therapeutics, which was developing a novel cell therapy for type-1 diabetes until it was acquired by Vertex.
  • Ms. Fenton joined Semma Therapeutics from Achillion Pharmaceuticals, where she served as Chief Financial Officer from 2006 to 2018.

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Wednesday, March 3, 2021 - 9:01pm

The Phase 1/2 study will enroll up to 130 patients with a p53 Y220C mutation as determined by next generation sequencing.

Key Points: 
  • The Phase 1/2 study will enroll up to 130 patients with a p53 Y220C mutation as determined by next generation sequencing.
  • Phase 2 will assess the overall response rate and duration of response at the PC14586 dose identified in Phase 1.
  • PMV Pharma ended the fourth quarter with $361.4 million in cash, cash equivalents, and marketable securities, compared to $101.5 million as of December 31, 2019.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline

Wednesday, March 3, 2021 - 12:00pm

PHILADELPHIA, March 3, 2021 /PRNewswire/ -- Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing.

Key Points: 
  • PHILADELPHIA, March 3, 2021 /PRNewswire/ -- Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing.
  • Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.
  • Funds raised will help advance Century's rich pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products.
  • Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies.

Global Sepsis Diagnostics Markets, 2016-2020 & 2021-2027 - Instruments, Blood Culture Media, Assay Kits & Reagents, Software

Tuesday, March 2, 2021 - 10:15pm

Moreover, the favorable reimburse scenario in developed economies and burgeoning healthcare infrastructure in low and middle-income countries is expected to propel market growth.

Key Points: 
  • Moreover, the favorable reimburse scenario in developed economies and burgeoning healthcare infrastructure in low and middle-income countries is expected to propel market growth.
  • In terms of product, the market is segmented into instruments, blood culture media, assay kits and reagents, and software.
  • Based on technology, the market is further bifurcated into microbiology, molecular diagnostics, biomarkers, immunoassays, and flow cytometry.
  • The blood culture media segment accounted for the largest revenue share of the global market as it is used in maximum cases for diagnosis.

New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs

Tuesday, March 2, 2021 - 1:00pm

Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Key Points: 
  • Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.
  • Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing.
  • Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers.
  • Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes

Tuesday, March 2, 2021 - 12:00pm

ViaCyte has demonstrated that when the cells successfully engraft, they produce both insulin and glucagon in T1D patients, a first in the field of cell therapy for diabetes.

Key Points: 
  • ViaCyte has demonstrated that when the cells successfully engraft, they produce both insulin and glucagon in T1D patients, a first in the field of cell therapy for diabetes.
  • ViaCyte is currently evaluating open and closed devices to deliver cell replacement therapies for type 1 diabetes (T1D) in Phase 2 clinical trials.
  • These devices contain the cell therapy while enabling oxygen and nutrients to flow into the device and insulin, glucagon, and other hormones to flow out.
  • www.gore.com
    ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation.

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

Monday, March 1, 2021 - 8:45pm

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021.

Key Points: 
  • CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021.
  • Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Global Immuno-oncology Market Report 2020: I-O Market is Expected to Reach $132.66 Billion by 2025, Growing at a Rate of 11.6% and Witness Minimal Impact From COVID-19

Monday, March 1, 2021 - 4:00pm

Why Is It Increasingly Difficult to Grow?

Key Points: 
  • Why Is It Increasingly Difficult to Grow?
  • Key Findings for the Immuno-oncology Market-Rising Incidences of Cancer, R&D Portfolio Management, and Regulatory Pathways
    Key Findings for the Immuno-oncology Market-Breakthrough Innovations, Program Acceleration, and Smart Production
    Marketed Product Dashboard-Adoptive Cell TherapyYescarta (KTE-C19, axicabtagene ciloleucel): Kite Pharma-Gilead
    Marketed Product Dashboard-Adoptive Cell TherapyKymriah (CTL019, tisagenlecleucel): Novartis
    Pipeline Product Dashboard-Adoptive Cell TherapyIdecabtagene Vicleucel (ide-cel, bb2121): Bristol-Myers Squibb
    Pipeline Product Dashboard-Checkpoint InhibitorCamrelizumab (AiRuiKaT, SHR-1210): Jiangsu HengRui Medicine
    Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020
    Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Call to Action
    Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combinations
    Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combination Cases
    Growth Opportunity 1: I-O Therapy Combinations for Enhancing Efficacy, 2020-Combination Cases (continued)
    Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020
    Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Call to Action
    Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Business Model
    Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Smart Facilities
    Growth Opportunity 2: Decentralized Satellite Manufacturing for Making Cell Therapy Affordable, 2020-Smart Cell Cases
    Growth Opportunity 3: Novel Engineering Platforms for Support Precision Oncology, 2020
    Growth Opportunity 3: Novel Engineering Platforms for Supporting Precision Oncology, 2020-Call to Action
    Growth Opportunity 3: Novel Engineering Platforms for Support Precision Oncology, 2020-Biotech Platforms
    Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020
    Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Call to Action
    Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Strategies
    Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020- Biomarkers
    Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Relevant Cases
    Growth Opportunity 4: Biomarkers Boosting Companion Diagnostics for Response Prediction and Immune Evolution Monitoring, 2020-Relevant Cases (continued)
    Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020
    Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Call to Action
    Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-New Approaches
    Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Improved Measures
    Growth Opportunity 5: New Validation Frameworks for I-O into Standard of Care Practice, 2020-Tele-oncology Landscape
    Growth Opportunity 6: Asia-Pacific in the Spotlight for Accelerating I-O Programs, 2020
    Growth Opportunity 6: Asia-Pacific in the Spotlight for Accelerating I-O Programs, 2020-Call to Action